188 related articles for article (PubMed ID: 31286322)
21. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Barrio S; Gallardo M; Arenas A; Ayala R; Rapado I; Rueda D; Jiménez-Ubieto A; Albizua E; Burgaleta C; Gilsanz F; Martinez-Lopez J
Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
[TBL] [Abstract][Full Text] [Related]
23. [leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].
Fan C; Zhang Y; Yang R; Wu X; Zhou J; Xue J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):207-214. PubMed ID: 38512030
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
25. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
26. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
28. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
[TBL] [Abstract][Full Text] [Related]
29. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M; Maifrede S; Dasgupta Y; Sullivan K; Flis S; Le BV; Solecka M; Belyaeva EA; Kubovcakova L; Nawrocki M; Kirschner M; Zhao H; Prchal JT; Piwocka K; Moliterno AR; Wasik M; Koschmieder S; Green TR; Skoda RC; Skorski T
Blood; 2017 Dec; 130(26):2848-2859. PubMed ID: 29042365
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
Guvenir Celik E; Eroglu O
Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
[TBL] [Abstract][Full Text] [Related]
33. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
35. Targeting glutamine metabolism in myeloproliferative neoplasms.
Zhan H; Ciano K; Dong K; Zucker S
Blood Cells Mol Dis; 2015 Oct; 55(3):241-7. PubMed ID: 26227854
[TBL] [Abstract][Full Text] [Related]
36. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
37. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
Rai S; Grockowiak E; Hansen N; Luque Paz D; Stoll CB; Hao-Shen H; Mild-Schneider G; Dirnhofer S; Farady CJ; Méndez-Ferrer S; Skoda RC
Nat Commun; 2022 Sep; 13(1):5346. PubMed ID: 36100613
[TBL] [Abstract][Full Text] [Related]
39. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
40. Exploring redox vulnerabilities in JAK2
Lima K; Lopes LR; Machado-Neto JA
Hematol Transfus Cell Ther; 2021; 43(4):430-436. PubMed ID: 32962959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
